文献速递免疫规划传染病防控与疫情报告

阿富汗口服脊髓灰质炎疫苗效果评估(2010-2020)

Estimation of oral poliovirus vaccine effectiveness in Afghanistan, 2010-2020.
PubMed 文献 · Vaccine · 2021-09-16

该研究采用匹配病例对照分析,利用2010至2020年阿富汗29,370名15岁以下急性弛缓性麻痹儿童的监测数据,评估口服脊髓灰质炎疫苗(OPV)预防1型野生脊髓灰质炎病毒(WPV1)所致麻痹的效果。结果显示,OPV每剂效果估计为19%(95%CI:15%-22%),接种≥7剂效果达94%(95%CI:90%-97%);2016年4月全球从三价OPV(tOPV)转换为二价OPV(bOPV)后,每剂效果为32%(24%-39%),≥7剂效果为96%(95%CI:90%-99%)。结论认为阿富汗WPV1持续传播源于疫苗接种失败而非疫苗失效。

要点

  • OPV每剂对WPV1所致麻痹的效果为19%,接种≥7剂效果达94%。
  • tOPV转换为bOPV后,每剂效果升至32%,≥7剂效果为96%。
  • 阿富汗WPV1持续传播归因于未能接种疫苗,而非疫苗失效。

核心结论

  • OPV对预防WPV1所致麻痹高度有效,阿富汗WPV1持续传播是由于疫苗接种失败而非疫苗失效。

研究设计与样本

  • 将确诊WPV1病例与非脊髓灰质炎急性弛缓性麻痹对照按麻痹发病年龄(±3个月)、麻痹发病日期(±3个月)和居住省份进行匹配。
  • 采用条件逻辑回归比较报告的口服脊髓灰质炎疫苗接种史以估计效果,并根据2016年4月全球从三价OPV(tOPV)转换为二价OPV(bOPV)的日期进行分层分析。

主要发现

  • OPV每剂对WPV1的估计效果为19%(95%CI:15%-22%),接种≥7剂的效果为94%(95%CI:90%-97%)。
  • 全球从tOPV转换为bOPV之前,OPV每剂估计效果为14%(95%CI:11%-18%),≥7剂效果为92%(95%CI:85%-96%)。
  • 转换之后,OPV每剂对WPV1的估计效果为32%(24%-39%),≥7剂效果为96%(95%CI:90%-99%)。

临床怎么用

  • 应加强常规免疫和补充免疫活动中OPV的接种实施,以提高接种覆盖率。
  • 尽管阿富汗部分地区实施困难,改善OPV接种管理对实现脊髓灰质炎根除至关重要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Afghanistan is one of two countries with endemic wild poliovirus type 1 (WPV1). The oral poliovirus vaccine (OPV) is the predominant vaccine used for polio eradication. Although OPV has been administered in routine childhood immunization and during frequent supplementary immunization activities, WPV1 continues to circulate in Afghanistan and case incidence has been increasing since 2017. We estimated the effectiveness of OPV in Afghanistan during 2010-2020. METHODS: We conducted a matched case-control analysis using acute flaccid paralysis (AFP) surveillance data from 29,370 children < 15 years with AFP onset between January 1, 2010 and December 31, 2020. We matched children with confirmed WPV1 (cases) with children with non-polio AFP (controls) by age at onset of paralysis (+/- 3 months), date of onset of paralysis (+/- 3 months), and province of residence, and compared their reported OPV vaccination history to estimate the effectiveness of OPV in preventing paralysis by WPV1 using conditional logistic regression. To account for changes in OPV formulations provided over the analysis period, we stratified the analysis based on dates of the global switch from trivalent OPV (tOPV) to bivalent OPV (bOPV) in April 2016. RESULTS: Between January 1, 2010 and December 31, 2020, there were 329 WPV1 cases in Afghanistan. The per-dose estimated effectiveness of OPV against WPV1 was 19% (95% CI: 15%-22%) and of ≥ 7 doses was 94% (95% CI: 90%-97%). Before the global switch from tOPV to bOPV, the per-dose estimated effectiveness of OPV was 14% (95% CI: 11%-18%) and of ≥ 7 doses was 92% (95% CI: 85%-96%). After the switch, the per-dose estimated effectiveness of OPV against WPV1 was 32% (24%-39%) and of ≥ 7 doses was 96% (95% CI: 90%-99%). DISCUSSION: OPV is highly effective in preventing paralysis by WPV1; these results indicate that continued WPV1 transmission in Afghanistan is due to failure to vaccinate, not failure of the vaccine. Although difficult to implement in parts of country, improving the administration of OPV in routine immunization and supplementary immunization activities will be critical for achieving polio eradication in Afghanistan.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chard AN, Martinez M, Matanock A, et al. Estimation of oral poliovirus vaccine effectiveness in Afghanistan, 2010-2020. Vaccine. 2021. PMID: 34538696. doi:10.1016/j.vaccine.2021.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。